SF 2470

1st Unofficial Engrossment - 88th Legislature (2013 - 2014)

Posted on 05/07/2014 11:13 a.m.

1.1A bill for an act 1.2relating to health; adopting the Medical Cannabis Therapeutic Research Act; 1.3requiring clinical trials on the therapeutic use of medical cannabis; setting 1.4standards for clinical trials; requiring the commissioner to contract with one 1.5manufacturer for medical cannabis products; requiring an impact assessment 1.6of medical cannabis therapeutic research; setting fees; requiring reports; 1.7appropriating money;amending Minnesota Statutes 2012, section 256B.0625, 1.8subdivision 13d; proposing coding for new law in Minnesota Statutes, chapter 1.9152. 1.10BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA: 1.11    Section 1. new text begin [152.22] MEDICAL CANNABIS THERAPEUTIC RESEARCH ACT. new text end 1.12     new text begin Subdivision 1. new text end new text begin Findings and purpose. new text end new text begin (a) The legislature finds that scientific new text end 1.13 new text begin literature indicates promise for medical cannabis in alleviating certain intractable medical new text end 1.14 new text begin conditions under strictly controlled medical circumstances. new text end 1.15 new text begin (b) The legislature also finds that further research and strictly controlled new text end 1.16 new text begin experimentation regarding the therapeutic use of medical cannabis is necessary and new text end 1.17 new text begin desirable. The intent of this section is to establish clinical trials to investigate and report new text end 1.18 new text begin on the therapeutic effects of medical cannabis. The intent of the legislature is to allow new text end 1.19 new text begin the greatest possible access to patients with a qualifying medical condition residing in new text end 1.20 new text begin Minnesota who meet protocol requirements for these clinical trials. The establishment of new text end 1.21 new text begin this research program is not intended in any manner whatsoever to condone or promote new text end 1.22 new text begin the illicit recreational use of marijuana. new text end 1.23     new text begin Subd. 2. new text end new text begin Definitions. new text end new text begin (a) For purposes of this section, the following terms have new text end 1.24 new text begin the meanings given. new text end 2.1 new text begin (b) "Clinical investigators" means a Minnesota licensed doctor of medicine, a new text end 2.2 new text begin Minnesota licensed physician assistant acting within the scope of authorized practice, or new text end 2.3 new text begin a Minnesota licensed advance practice registered nurse. new text end 2.4 new text begin (c) "Commissioner" means the commissioner of health. new text end 2.5 new text begin (d) "Medical cannabis" means the flowers of any species of the genus cannabis new text end 2.6 new text begin plant, or any mixture or preparation of them, including extracts and resins which new text end 2.7 new text begin contain a chemical consistency of cannabidiols and tetrahydrocannabinols determined new text end 2.8 new text begin to be medically beneficial by the principal investigator under subdivision 4 or by the new text end 2.9 new text begin commissioner under subdivision 3, paragraph (d), and that is delivered in the form of: new text end 2.10 new text begin (1) liquid, including, but not limited to, oil; new text end 2.11 new text begin (2) pill; or new text end 2.12 new text begin (3) vaporized delivery method, which does not include smoking, with in-person new text end 2.13 new text begin supervision by a clinical investigator, as specified under subdivision 5. new text end 2.14 new text begin (e) "Medical cannabis manufacturer" means an entity under contract with the new text end 2.15 new text begin commissioner to cultivate, acquire, manufacture, possess, prepare, transfer, transport, new text end 2.16 new text begin supply, or dispense medical cannabis, delivery devices, or related supplies and educational new text end 2.17 new text begin materials to patients with a qualifying medical condition who are participating in a clinical new text end 2.18 new text begin trial. new text end 2.19 new text begin (f) "Medical cannabis product" means medical cannabis as defined in paragraph new text end 2.20 new text begin (d) and any delivery device or related supplies and educational materials used in the new text end 2.21 new text begin administration of a medical cannabis clinical trial for a patient with a qualifying medical new text end 2.22 new text begin condition. new text end 2.23 new text begin (g) "Principal investigator" means an individual or organization with responsibility new text end 2.24 new text begin for the medical and scientific aspects of the research, development of protocol, and new text end 2.25 new text begin contacting and qualifying the clinical investigators in the state, and duties as provided new text end 2.26 new text begin in subdivision 3, paragraph (d). new text end 2.27 new text begin (h) "Program" means the clinical trial research program established pursuant to new text end 2.28 new text begin this section. new text end 2.29 new text begin (i) "Qualifying medical condition" means a diagnosis of the following conditions: new text end 2.30 new text begin (1) cancer; new text end 2.31 new text begin (2) glaucoma; new text end 2.32 new text begin (3) human immunodeficiency virus or acquired immune deficiency syndrome; new text end 2.33 new text begin (4) Tourette's syndrome; new text end 2.34 new text begin (5) amyotrophic lateral sclerosis; new text end 2.35 new text begin (6) seizures, including those characteristic of epilepsy; new text end 3.1 new text begin (7) severe and persistent muscle spasms, including those characteristic of multiple new text end 3.2 new text begin sclerosis; new text end 3.3 new text begin (8) Crohn's disease; or new text end 3.4 new text begin (9) any other medical condition or its treatment approved by the commissioner. new text end 3.5     new text begin Subd. 3. new text end new text begin Clinical trials administration. new text end new text begin (a) The commissioner of health shall new text end 3.6 new text begin contract with one or more principal investigators to conduct clinical trials for Minnesota new text end 3.7 new text begin resident patients with a qualifying medical condition regarding the therapeutic use of new text end 3.8 new text begin medical cannabis. As a condition of the contract, the commissioner shall require a new text end 3.9 new text begin principal investigator to: new text end 3.10 new text begin (1) begin the patient testing phase of a clinical trial by July 1, 2015; new text end 3.11 new text begin (2) develop guidelines and protocols necessary to establish empirical bases for new text end 3.12 new text begin the evaluation of medical cannabis as a medically recognized therapeutic substance. new text end 3.13 new text begin The guidelines and protocols shall ensure that stringent security and record-keeping new text end 3.14 new text begin requirements for the clinical trial are met and that participants in the program meet new text end 3.15 new text begin research standards; new text end 3.16 new text begin (3) disclose to all patients the experimental nature of the program and the possible new text end 3.17 new text begin risks and side effects of the proposed treatment and shall provide the program applicants new text end 3.18 new text begin with the Tennessen warning as required by section 13.04, subdivision 2; and new text end 3.19 new text begin (4) comply with the requirements of subdivision 4. new text end 3.20 new text begin (b) The principal investigator may contract with additional qualified entities to assist new text end 3.21 new text begin in fulfilling the requirements of this section. new text end 3.22 new text begin (c) The commissioner shall provide an option to opt out of any placebo trials for new text end 3.23 new text begin patients under age 18 with a qualifying condition. The decision to opt out of placebo trials new text end 3.24 new text begin under this paragraph may only be made by a patient's parent or legal guardian. new text end 3.25 new text begin (d) If a principal investigator is unavailable to evaluate one or more of the qualifying new text end 3.26 new text begin medical conditions, the commissioner shall fulfill the responsibilities of the principal new text end 3.27 new text begin investigator described in this section for that qualifying medical condition. new text end 3.28 new text begin (e) The commissioner may approve the participation of Minnesota residents in a new text end 3.29 new text begin federally approved clinical trial testing the effects of medical cannabis on one or more new text end 3.30 new text begin of the qualifying medical conditions listed in subdivision 2, paragraph (i), subject to the new text end 3.31 new text begin continuance of clinical trials for all other qualifying medical conditions. new text end 3.32 new text begin (f) Nothing in this section requires the medical assistance and MinnesotaCare new text end 3.33 new text begin programs to reimburse an enrollee or a provider for costs associated with the medical use new text end 3.34 new text begin of marijuana. new text end 3.35     new text begin Subd. 4. new text end new text begin Principal investigator duties. new text end new text begin A principal investigator shall: new text end 4.1 new text begin (1) give notice of the program to every health care provider in the state who is new text end 4.2 new text begin eligible to serve as a clinical investigator as defined in subdivision 2, paragraph (b), and new text end 4.3 new text begin explain the purposes and requirements of the program; new text end 4.4 new text begin (2) allow each clinical investigator in the state who meets or agrees to meet the new text end 4.5 new text begin principal investigator's requirements, has adequate institutional support, and who requests new text end 4.6 new text begin to participate, to be included in the research program as a clinical investigator to conduct new text end 4.7 new text begin the clinical trials; new text end 4.8 new text begin (3) provide explanatory information and assistance to each clinical investigator new text end 4.9 new text begin in understanding the nature of therapeutic use of medical cannabis within program new text end 4.10 new text begin requirements, including the informed consent document contained in the protocol, and new text end 4.11 new text begin inform and counsel patients involved in the program regarding the appropriate use and the new text end 4.12 new text begin effects of therapeutic use of medical cannabis; new text end 4.13 new text begin (4) supervise the participation of the clinical investigator in conducting the clinical new text end 4.14 new text begin trials; new text end 4.15 new text begin (5) obtain medical cannabis for this clinical trial from the medical cannabis new text end 4.16 new text begin manufacturer which meets the requirements in subdivision 6; new text end 4.17 new text begin (6) determine the chemical consistency of cannabidiols and tetrahydrocannabinols new text end 4.18 new text begin that are medically beneficial for each qualifying medical condition investigated; new text end 4.19 new text begin (7) regulate the proper storage and distribution of medical cannabis products to new text end 4.20 new text begin patients with a qualifying condition, including monitoring the chain of custody; new text end 4.21 new text begin (8) distribute medical cannabis products to clinical investigators for each individual new text end 4.22 new text begin patient after ensuring that the medical cannabis products are properly labeled for each new text end 4.23 new text begin individual patient pursuant to section 151.212 and related rules; new text end 4.24 new text begin (9) develop safety criteria for patients with a qualifying condition as a requirement new text end 4.25 new text begin of the patient's participation in the program, to prevent the patient from undertaking new text end 4.26 new text begin any task under the influence of medical cannabis that would constitute negligence or new text end 4.27 new text begin professional malpractice; new text end 4.28 new text begin (10) submit periodic reports as determined by the commissioner on the numbers of new text end 4.29 new text begin patients involved in the program and the results of the program; new text end 4.30 new text begin (11) submit reports on intermediate or final research results to the commissioner, the new text end 4.31 new text begin legislature, and major scientific journals; and new text end 4.32 new text begin (12) otherwise comply with the provisions of this section. new text end 4.33     new text begin Subd. 5. new text end new text begin Clinical investigator duties. new text end new text begin (a) A clinical investigator shall: new text end 4.34 new text begin (1) enroll patients with a qualifying medical condition in the clinical trials; new text end 4.35 new text begin (2) participate in the clinical trials under the guidance and supervision of a principal new text end 4.36 new text begin investigator; new text end 5.1 new text begin (3) provide explanatory information from the principal investigator to patients with new text end 5.2 new text begin qualifying medical conditions; new text end 5.3 new text begin (4) advise patients and parents or legal guardians of patients under age 18 of the new text end 5.4 new text begin existence of any nonprofit patient support groups or organizations; new text end 5.5 new text begin (5) determine, in consultation with the patients, parents or legal guardians of patients new text end 5.6 new text begin under age 18, and the principal investigator, the proper dosage of medical cannabis for new text end 5.7 new text begin each individual patient; new text end 5.8 new text begin (6) obtain from the principal investigator all medical cannabis products needed for new text end 5.9 new text begin each individual patient; new text end 5.10 new text begin (7) ensure that medical cannabis products are properly labeled by the principal new text end 5.11 new text begin investigator for each individual patient prior to distribution to the patient; new text end 5.12 new text begin (8) distribute properly labeled medical cannabis products to patients or provide the new text end 5.13 new text begin patient with information and instructions on obtaining properly labeled medical cannabis new text end 5.14 new text begin from a qualified employee of a principal investigator with responsibility for distributing new text end 5.15 new text begin medical cannabis under subdivision 4, clause (8); new text end 5.16 new text begin (9) provide in-person supervision for the administration of any vaporized delivery new text end 5.17 new text begin method of medical cannabis; new text end 5.18 new text begin (10) report findings from the clinical trial to the principal investigator in a manner new text end 5.19 new text begin determined by the principal investigator; and new text end 5.20 new text begin (11) otherwise comply with all requirements developed by the supervising principal new text end 5.21 new text begin investigator. new text end 5.22 new text begin (b) A patient's enrollment in a clinical trial may not be denied based on the use of new text end 5.23 new text begin medical cannabis in a jurisdiction outside of Minnesota. Enrollment shall only be denied new text end 5.24 new text begin if the patient has not been diagnosed with a qualifying medical condition. new text end 5.25     new text begin Subd. 6. new text end new text begin Manufacturer of medical cannabis. new text end new text begin (a) The commissioner shall contract new text end 5.26 new text begin with one manufacturer for the production of all medical cannabis products within the state new text end 5.27 new text begin by December 1, 2014, unless the commissioner obtains an adequate supply of federally new text end 5.28 new text begin sourced medical cannabis products for the clinical trials no later than August 1, 2014. new text end 5.29 new text begin The commissioner shall continue to accept applications after December 1, 2014, if no new text end 5.30 new text begin manufacturer that meets the qualifications set forth in this subdivision applies prior to new text end 5.31 new text begin December 1, 2014. If a federally approved source of medical cannabis becomes available new text end 5.32 new text begin after December 1, 2014, the commissioner may obtain the federally approved medical new text end 5.33 new text begin cannabis in addition to medical cannabis from the contracted manufacturer within the new text end 5.34 new text begin state of Minnesota. new text end 5.35 new text begin (b) The operating documents of the manufacturer must include procedures for the new text end 5.36 new text begin oversight of the manufacturer and procedures to ensure accurate record keeping. new text end 6.1 new text begin (c) The manufacturer shall implement appropriate security measures to deter and new text end 6.2 new text begin prevent the theft of cannabis and unauthorized entrance into areas containing cannabis. new text end 6.3 new text begin (d) All cultivation, harvesting, manufacturing, and packing of cannabis must take new text end 6.4 new text begin place in an enclosed, locked facility at a physical address provided to the commissioner new text end 6.5 new text begin during the contracting process. new text end 6.6 new text begin (e) Prior to distribution of any medical cannabis to the principal investigator, or the new text end 6.7 new text begin commissioner acting as the principal investigator under subdivision 3, paragraph (d), the new text end 6.8 new text begin manufacturer must process and prepare any cannabis plant material into a form allowable new text end 6.9 new text begin under subdivision 2, paragraph (d). new text end 6.10 new text begin (f) The manufacturer shall not share office space with or refer patients to a practitioner. new text end 6.11 new text begin (g) The manufacturer shall not permit any person to consume cannabis on the new text end 6.12 new text begin property of the manufacturer. new text end 6.13 new text begin (h) The manufacturer is subject to reasonable inspection by the commissioner. new text end 6.14 new text begin (i) The manufacturer may not employ or otherwise allow any person who is under new text end 6.15 new text begin 21 years of age to be an agent of the manufacturer. new text end 6.16 new text begin (j) All products manufactured must be tested as to content, contamination, and new text end 6.17 new text begin consistency by a certified laboratory to verify such products meet the requirements of new text end 6.18 new text begin subdivision 2, paragraph (d). new text end 6.19 new text begin (k) The medical cannabis manufacturer shall produce medical cannabis with a new text end 6.20 new text begin chemical consistency of cannabidiols and tetrahydrocannabinols as determined by the new text end 6.21 new text begin principal investigator. new text end 6.22 new text begin (l) For the purposes of this section only, the manufacturer of medical cannabis new text end 6.23 new text begin products is not required to be licensed under section 151.252 or 151.47. new text end 6.24     new text begin Subd. 7. new text end new text begin Confidentiality. new text end new text begin (a) Data in patient files with both the clinical investigator new text end 6.25 new text begin and the principal investigator, and data submitted to or by the medical cannabis new text end 6.26 new text begin manufacturer are private data on individuals or nonpublic data as defined in section 13.02. new text end 6.27 new text begin (b) Data kept or maintained by the commissioner may not be used for any purpose new text end 6.28 new text begin not provided for in this section and may not be combined or linked in any manner with new text end 6.29 new text begin any other list or database. new text end 6.30     new text begin Subd. 8. new text end new text begin Protections for clinical trial participation; criminal and civil. new text end new text begin (a) There new text end 6.31 new text begin is a presumption that a patient enrolled in a clinical trial under this section is engaged in new text end 6.32 new text begin the authorized use of medical cannabis. new text end 6.33 new text begin (b) The presumption may be rebutted by evidence that conduct related to use of new text end 6.34 new text begin medical cannabis was not for the purpose of treating or alleviating the patient's qualifying new text end 6.35 new text begin medical condition or symptoms associated with the patient's qualifying medical condition new text end 6.36 new text begin pursuant to this section. new text end 7.1 new text begin (c) For the purposes of this section only, the following are not violations under new text end 7.2 new text begin this chapter: new text end 7.3 new text begin (1) use or possession of medical cannabis by a patient in the clinical trials program, new text end 7.4 new text begin or possession by the parent or guardian of a patient under age 18; new text end 7.5 new text begin (2) possession of, prescribing the use of, administering, or dispensing of medical new text end 7.6 new text begin cannabis, or any combination of these actions, by the principal investigator or by any new text end 7.7 new text begin clinical investigator; new text end 7.8 new text begin (3) possession or sale of medical cannabis by a pharmacy or the medical cannabis new text end 7.9 new text begin manufacturer which produces or stores medical cannabis on behalf of the principal new text end 7.10 new text begin investigator or a clinical investigator; and new text end 7.11 new text begin (4) possession of medical cannabis products by any person while carrying out the new text end 7.12 new text begin duties required under this section. new text end 7.13 new text begin (d) Medical cannabis obtained and distributed pursuant to this section and associated new text end 7.14 new text begin property is not subject to forfeiture under sections 609.531 to 609.5316. new text end 7.15 new text begin (e) A principal or clinical investigator is not subject to any civil or disciplinary new text end 7.16 new text begin penalties by the Board of Medical Practice or by any business, occupational, or new text end 7.17 new text begin professional licensing board or entity solely for the investigator's participation in a clinical new text end 7.18 new text begin trial under this section. Nothing in this section prohibits a professional licensing board new text end 7.19 new text begin for sanctioning a principal or clinical investigator for an investigator's actions outside of new text end 7.20 new text begin those actions allowed under this section. new text end 7.21 new text begin (f) For the purposes of this section only, medical cannabis is removed from Schedule new text end 7.22 new text begin I contained in section 152.02, subdivision 2, and inserted in Schedule II contained in new text end 7.23 new text begin section 152.02, subdivision 3. new text end 7.24     new text begin Subd. 9. new text end new text begin Discrimination prohibited. new text end new text begin (a) No school or landlord may refuse to new text end 7.25 new text begin enroll or lease to and may not otherwise penalize a person solely for the person's status new text end 7.26 new text begin as a patient enrolled in a clinical trial under this section, unless failing to do so would new text end 7.27 new text begin violate federal law or regulations or cause the school or landlord to lose a monetary or new text end 7.28 new text begin licensing-related benefit under federal law or regulations. new text end 7.29 new text begin (b) For the purposes of medical care, including organ transplants, a clinical trial new text end 7.30 new text begin enrollee's use of medical cannabis under this section is considered the equivalent of the new text end 7.31 new text begin authorized use of any other medication used at the discretion of a physician and does new text end 7.32 new text begin not constitute the use of an illicit substance or otherwise disqualify a qualifying patient new text end 7.33 new text begin from needed medical care. new text end 7.34 new text begin (c) Unless a failure to do so would violate federal law or regulations or cause an new text end 7.35 new text begin employer to lose a monetary or licensing-related benefit under federal law or regulations, new text end 7.36 new text begin an employer may not discriminate against a person in hiring, termination, or any term or new text end 8.1 new text begin condition of employment, or otherwise penalize a person, if the discrimination is based new text end 8.2 new text begin upon either of the following: new text end 8.3 new text begin (1) the person's status as a patient enrolled in a program under this section; or new text end 8.4 new text begin (2) a patient's positive drug test for cannabis components or metabolites, unless the new text end 8.5 new text begin patient used, possessed, or was impaired by medical cannabis on the premises of the place new text end 8.6 new text begin of employment or during the hours of employment. new text end 8.7 new text begin (d) A person shall not be denied custody of or visitation rights or parenting time with new text end 8.8 new text begin a minor solely for the person's status as a patient enrolled in a program under this section, new text end 8.9 new text begin and there shall be no presumption of neglect or child endangerment for conduct allowed new text end 8.10 new text begin under this section, unless the person's behavior is such that it creates an unreasonable new text end 8.11 new text begin danger to the safety of the minor as established by clear and convincing evidence. new text end 8.12     new text begin Subd. 10. new text end new text begin Fees. new text end new text begin The commissioner may set reasonable application fees and new text end 8.13 new text begin renewal fees to be paid to the commissioner by a patient with a qualifying medical new text end 8.14 new text begin condition that covers the fees incurred in manufacturing medical cannabis by the medical new text end 8.15 new text begin cannabis manufacturer. Fees collected must be deposited in the special revenue fund new text end 8.16 new text begin and are appropriated annually to the commissioner to reimburse costs incurred by the new text end 8.17 new text begin manufacturer of medical cannabis. The commissioner shall establish a sliding scale of new text end 8.18 new text begin patient fees based upon a qualifying patient's household income. The commissioner may new text end 8.19 new text begin accept private donations to reduce patient fees. new text end 8.20     new text begin Subd. 11. new text end new text begin Nursing facilities. new text end new text begin Nursing facilities licensed under chapter 144A, or new text end 8.21 new text begin boarding care homes licensed under section 144.50, may adopt reasonable restrictions new text end 8.22 new text begin on the use of medical cannabis by persons receiving inpatient services. The restrictions new text end 8.23 new text begin may include a provision that the facility will not store or maintain the patient's supply of new text end 8.24 new text begin medical cannabis, that the facility is not responsible for providing the medical cannabis for new text end 8.25 new text begin qualifying patients, and that cannabis be consumed only in a place specified by the facility. new text end 8.26 new text begin Nothing contained in this section shall require the facilities to adopt such restrictions, and no new text end 8.27 new text begin facility shall unreasonably limit a qualifying patient's access to or use of medical cannabis. new text end 8.28    Sec. 2. Minnesota Statutes 2012, section 256B.0625, subdivision 13d, is amended to 8.29read: 8.30    Subd. 13d. Drug formulary. (a) The commissioner shall establish a drug 8.31formulary. Its establishment and publication shall not be subject to the requirements of the 8.32Administrative Procedure Act, but the Formulary Committee shall review and comment 8.33on the formulary contents. 8.34    (b) The formulary shall not include: 9.1    (1) drugs, active pharmaceutical ingredients, or products for which there is no 9.2federal funding; 9.3    (2) over-the-counter drugs, except as provided in subdivision 13; 9.4    (3) drugs or active pharmaceutical ingredients used for weight loss, except that 9.5medically necessary lipase inhibitors may be covered for a recipient with type II diabetes; 9.6    (4) drugs or active pharmaceutical ingredients when used for the treatment of 9.7impotence or erectile dysfunction; 9.8    (5) drugs or active pharmaceutical ingredients for which medical value has not 9.9been established; and 9.10    (6) drugs from manufacturers who have not signed a rebate agreement with the 9.11Department of Health and Human Services pursuant to section 1927 of title XIX of the 9.12Social Security Act new text begin ; and new text end 9.13     new text begin (7) medical cannabis as defined under section 152.22 new text end . 9.14    (c) If a single-source drug used by at least two percent of the fee-for-service 9.15medical assistance recipients is removed from the formulary due to the failure of the 9.16manufacturer to sign a rebate agreement with the Department of Health and Human 9.17Services, the commissioner shall notify prescribing practitioners within 30 days of 9.18receiving notification from the Centers for Medicare and Medicaid Services (CMS) that a 9.19rebate agreement was not signed. 9.20    Sec. 3. new text begin IMPACT ASSESSMENT OF MEDICAL CANNABIS THERAPEUTIC new text end 9.21 new text begin RESEARCH. new text end 9.22     new text begin Subdivision 1. new text end new text begin Task force on medical cannabis therapeutic research. new text end new text begin (a) A new text end 9.23 new text begin 23-member task force on medical cannabis therapeutic research is created to conduct an new text end 9.24 new text begin impact assessment of medical cannabis therapeutic research. The task force shall consist new text end 9.25 new text begin of the following members: new text end 9.26 new text begin (1) two members of the house of representatives of the state of Minnesota, one new text end 9.27 new text begin selected by the speaker of the house, the other selected by the minority leader; new text end 9.28 new text begin (2) two members of the senate of the state of Minnesota, one selected by the majority new text end 9.29 new text begin leader, the other selected by the minority leader; new text end 9.30 new text begin (3) four members representing consumers or patients, including at least two parents new text end 9.31 new text begin of patients under age 18; new text end 9.32 new text begin (4) four members representing health care providers; new text end 9.33 new text begin (5) four members representing law enforcement, one from the Minnesota Chiefs of new text end 9.34 new text begin Police Association, one from the Minnesota Sheriff's Association, one from the Minnesota new text end 10.1 new text begin Police and Peace Officers Association, and one from the Minnesota County Attorneys new text end 10.2 new text begin Association; new text end 10.3 new text begin (6) four members representing substance use disorder treatment providers; and new text end 10.4 new text begin (7) the commissioners of health, human services, and public safety. new text end 10.5 new text begin (b) Task force members listed under paragraph (a), clauses (3), (4), (5), and (6), shall new text end 10.6 new text begin be appointed by the governor. Members shall serve on the task force at the pleasure of new text end 10.7 new text begin the appointing authority. new text end 10.8 new text begin (c) There shall be two cochairs of the task force chosen from the members listed new text end 10.9 new text begin under paragraph (a). One cochair shall be selected by the speaker of the house and new text end 10.10 new text begin the other cochair shall be selected by the majority leader of the senate. The expense new text end 10.11 new text begin reimbursement for members of the task force is governed by section 15.059. new text end 10.12     new text begin Subd. 2. new text end new text begin Impact assessment. new text end new text begin The task force shall hold hearings to conduct the new text end 10.13 new text begin impact assessment on medical cannabis therapeutic research that must evaluate Minnesota new text end 10.14 new text begin activities and other states' activities involving medical cannabis and offer analysis of: new text end 10.15 new text begin (1) program design and implementation; new text end 10.16 new text begin (2) the impact on the health care provider community; new text end 10.17 new text begin (3) patient experiences; new text end 10.18 new text begin (4) the impact on the incidence of substance abuse; new text end 10.19 new text begin (5) access to and quality of medical products; new text end 10.20 new text begin (6) the impact on law enforcement and prosecutions; new text end 10.21 new text begin (7) public awareness and perception; and new text end 10.22 new text begin (8) any unintended consequences. new text end 10.23     new text begin Subd. 3. new text end new text begin Reports to the legislature. new text end new text begin (a) The cochairs shall submit the following new text end 10.24 new text begin reports to the chairs and ranking minority members of the legislative committees and new text end 10.25 new text begin divisions with jurisdiction over health and human services, judiciary, and civil law: new text end 10.26 new text begin (1) by February 1, 2015, a report on the design and implementation of the clinical new text end 10.27 new text begin trial program; new text end 10.28 new text begin (2) by February 1, 2016, a final report on the impact assessment; and new text end 10.29 new text begin (3) by June 30, 2019, a review and assessment of the clinical trial results. new text end 10.30 new text begin (b) The task force may make recommendations to the legislature on whether to add new text end 10.31 new text begin or remove conditions from the list of qualifying medical conditions. new text end 10.32     new text begin Subd. 4. new text end new text begin Expiration. new text end new text begin The task force on medical cannabis therapeutic research new text end 10.33 new text begin expires on June 30, 2019, or upon the conclusion of the clinical trial, whichever is later. new text end 10.34    Sec. 4. new text begin APPROPRIATIONS; MEDICAL CANNABIS THERAPEUTIC new text end 10.35 new text begin RESEARCH ACT. new text end 11.1 new text begin (a) $1,100,000 in fiscal year 2016 and $1,100,000 in fiscal year 2017 are appropriated new text end 11.2 new text begin from the general fund to the commissioner of health for grants to the principal investigators new text end 11.3 new text begin for purposes of conducting the clinical trials under Minnesota Statutes, section 152.22. new text end 11.4 new text begin (b) $450,000 in fiscal year 2015 is appropriated from the general fund to the new text end 11.5 new text begin commissioner of health for the costs of administering Minnesota Statutes, section 152.22. new text end 11.6 new text begin Funds are available until June 30, 2019. new text end 11.7 new text begin (c) $50,000 in fiscal year 2015 is appropriated from the general fund to the new text end 11.8 new text begin Legislative Coordinating Commission to administer the task force on medical cannabis new text end 11.9 new text begin therapeutic research and for the task force to conduct the impact assessment on the use of new text end 11.10 new text begin cannabis for medicinal purposes. These funds are available until the expiration of the task new text end 11.11 new text begin force on medical cannabis therapeutic research. new text end 11.12    Sec. 5. new text begin EFFECTIVE DATE. new text end 11.13 new text begin Sections 1 and 3 are effective July 1, 2014. new text end